Apollon is a Korean-American medtech company building MOGLU, a needle-free continuous glucose monitor that reads blood sugar through the skin using Raman spectroscopy instead of a subcutaneous filament. Founded in Seoul in 2021 by Aram Hong and researchers tied to MIT and Asan Medical Center, the company is developing a compact wearable that reported accuracy comparable to leading CGMs in early MIT clinical testing, has been granted FDA Breakthrough Device designation, and won a 2025 CES Innovation Award.
Aram Hong is the CEO and co-founder of Apollon, a Seoul-born, Cambridge-based medtech company building MOGLU, a needle-free continuous glucose monitor powered by Raman spectroscopy. A former EY advisor and Genoplan executive who moved his family from Seoul to Boston to scale the company alongside MIT researchers, Hong has turned a laser-and-optics idea into a CES 2025 Innovation Award honoree that, in peer-reviewed clinical testing, matched the accuracy of leading needle-based sensors from Abbott and Dexcom.